MX2022011579A - Agonistas del receptor farnesoide x para el tratamiento de enfermedades. - Google Patents
Agonistas del receptor farnesoide x para el tratamiento de enfermedades.Info
- Publication number
- MX2022011579A MX2022011579A MX2022011579A MX2022011579A MX2022011579A MX 2022011579 A MX2022011579 A MX 2022011579A MX 2022011579 A MX2022011579 A MX 2022011579A MX 2022011579 A MX2022011579 A MX 2022011579A MX 2022011579 A MX2022011579 A MX 2022011579A
- Authority
- MX
- Mexico
- Prior art keywords
- farnesoid
- treatment
- disease
- receptor agonists
- fxr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062991292P | 2020-03-18 | 2020-03-18 | |
| US202063069667P | 2020-08-24 | 2020-08-24 | |
| US202163140735P | 2021-01-22 | 2021-01-22 | |
| PCT/US2021/022786 WO2021188688A1 (en) | 2020-03-18 | 2021-03-17 | Farnesoid x receptor agonists for the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011579A true MX2022011579A (es) | 2022-11-30 |
Family
ID=77771857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011579A MX2022011579A (es) | 2020-03-18 | 2021-03-17 | Agonistas del receptor farnesoide x para el tratamiento de enfermedades. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230131804A1 (https=) |
| EP (1) | EP4121048A4 (https=) |
| JP (1) | JP7851856B2 (https=) |
| KR (1) | KR20220154801A (https=) |
| CN (4) | CN120732854A (https=) |
| AU (1) | AU2021240001A1 (https=) |
| BR (1) | BR112022018651A2 (https=) |
| CA (1) | CA3172205A1 (https=) |
| IL (1) | IL296539A (https=) |
| MX (1) | MX2022011579A (https=) |
| TW (1) | TWI895384B (https=) |
| WO (1) | WO2021188688A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113056271B (zh) | 2018-09-18 | 2024-10-29 | 奥加诺沃公司 | 法尼醇x受体激动剂及其用途 |
| WO2021188695A1 (en) | 2020-03-18 | 2021-09-23 | Metacrine, Inc. | Formulations of a farnesoid x receptor agonist |
| IL296532A (en) | 2020-03-18 | 2022-11-01 | Metacrine Inc | Crystal forms of farnesoid x receptor agonist |
| CN117018000B (zh) * | 2023-08-29 | 2025-01-28 | 东莞市东南部中心医院(东莞市东南部中医医疗服务中心) | 4-胆甾烯-3-酮在制备预防或治疗炎症性肠病药物中的应用 |
| CN120837611B (zh) * | 2025-09-22 | 2025-12-16 | 吉林大学 | 一种经鼻给药的司美格鲁肽制剂及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545964A1 (en) * | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| JP2018510866A (ja) * | 2015-03-13 | 2018-04-19 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 腸受容体を活性化させるための、ファルネソイドｘ受容体アゴニストでの、成体の潜在性自己免疫性糖尿病の治療 |
| EP3350166A4 (en) * | 2015-09-16 | 2019-05-01 | Metacrine, Inc. | FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF |
| JP2018536016A (ja) * | 2015-09-16 | 2018-12-06 | メタクリン，インク． | ファルネソイドｘ受容体アゴニストとその使用 |
| WO2017049173A1 (en) | 2015-09-16 | 2017-03-23 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| WO2018170173A1 (en) * | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| LT3609888T (lt) | 2017-03-15 | 2025-11-10 | Farnezoidinio x receptoriaus agonistai ir jų panaudojimas | |
| IL269068B (en) * | 2017-03-15 | 2022-09-01 | Metacrine Inc | Paranoid x receptor agonists and uses thereof |
| CN113056271B (zh) | 2018-09-18 | 2024-10-29 | 奥加诺沃公司 | 法尼醇x受体激动剂及其用途 |
-
2021
- 2021-03-17 CN CN202511190786.2A patent/CN120732854A/zh active Pending
- 2021-03-17 CN CN202511190792.8A patent/CN120732855A/zh active Pending
- 2021-03-17 CN CN202180036461.2A patent/CN115666559A/zh active Pending
- 2021-03-17 JP JP2022555913A patent/JP7851856B2/ja active Active
- 2021-03-17 EP EP21772019.2A patent/EP4121048A4/en active Pending
- 2021-03-17 TW TW110109622A patent/TWI895384B/zh active
- 2021-03-17 US US17/906,580 patent/US20230131804A1/en active Pending
- 2021-03-17 MX MX2022011579A patent/MX2022011579A/es unknown
- 2021-03-17 IL IL296539A patent/IL296539A/en unknown
- 2021-03-17 CN CN202511190799.XA patent/CN120732856A/zh active Pending
- 2021-03-17 BR BR112022018651A patent/BR112022018651A2/pt unknown
- 2021-03-17 AU AU2021240001A patent/AU2021240001A1/en active Pending
- 2021-03-17 KR KR1020227036071A patent/KR20220154801A/ko active Pending
- 2021-03-17 CA CA3172205A patent/CA3172205A1/en active Pending
- 2021-03-17 WO PCT/US2021/022786 patent/WO2021188688A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021188688A1 (en) | 2021-09-23 |
| TW202143961A (zh) | 2021-12-01 |
| US20230131804A1 (en) | 2023-04-27 |
| EP4121048A1 (en) | 2023-01-25 |
| TWI895384B (zh) | 2025-09-01 |
| JP2023518397A (ja) | 2023-05-01 |
| CA3172205A1 (en) | 2021-09-23 |
| CN115666559A (zh) | 2023-01-31 |
| CN120732856A (zh) | 2025-10-03 |
| KR20220154801A (ko) | 2022-11-22 |
| CN120732855A (zh) | 2025-10-03 |
| IL296539A (en) | 2022-11-01 |
| CN120732854A (zh) | 2025-10-03 |
| EP4121048A4 (en) | 2024-06-12 |
| JP7851856B2 (ja) | 2026-04-27 |
| BR112022018651A2 (pt) | 2022-11-29 |
| AU2021240001A1 (en) | 2022-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022011579A (es) | Agonistas del receptor farnesoide x para el tratamiento de enfermedades. | |
| EA202190661A1 (ru) | Агонисты фарнезоидного х-рецептора для лечения заболевания | |
| PH12021550882A1 (en) | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders | |
| PH12019501120A1 (en) | Methods of treating inflammatory conditions | |
| MX2017005875A (es) | Metodos para tratar enfermedades oculares. | |
| MX2020011562A (es) | Agonistas del receptor de la hormona tiroidea y usos de los mismos. | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| MX2024001201A (es) | Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con agonistas de glp-1 para usarse en tratar enfermedades del higado graso. | |
| BR112016000546A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
| PH12021550605A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| NZ746784A (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| MX2021011269A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina. | |
| MY199382A (en) | Methods of treating circadian rhythm sleep disorders | |
| BR112017024997A2 (pt) | tratamento de hipoglicemia pós-bariátrica com antagonistas de glp-1 | |
| ZA202506240B (en) | Semaglutide for the treatment of non-alcoholic steatohepatitis | |
| MX2019015741A (es) | Tratamiento con plasminogeno de afecciones asociadas a la sobreexpresion de pai-1. | |
| CL2019000914A1 (es) | Composiciones de combinaciones que comprenden agonistas de fxr para tratar o prevenir una enfermedad o un trastorno fibrótico o cirrótico. | |
| PH12021550671A1 (en) | Prodrugs of cgrp antagonists | |
| MX2022005474A (es) | Tratamiento de melanoma con antagonistas del gen 3 de activacion de linfocitos (lag-3). | |
| JOP20190040A1 (ar) | توليفة من ناهضات fxr | |
| JOP20250311A1 (ar) | مثبطات tyk2 وتركيبات وطرق لها | |
| MX2023008083A (es) | Tratamiento conjunto. | |
| MX2022011879A (es) | Derivados de trapidilo marcados isotopicamente. | |
| EP4461362A3 (en) | Nk1-antagonist combination and method for treating synucleinopathies | |
| BR112022005457A2 (pt) | Agente terapêutico ou profilático para caquexia |